2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5861 Identification and validation of CD180 as a safe and effective immunotherapeutic target in acute myeloid leukemia

Qianqian Huang, Yang Lu2, Leling Xie3, Chengcai Guo4, Simeng Li5, Yangtao Shangguan6, Wenbing Liu7, Yu Liu8, Fan Ding9, Haiyan Xing10, Kejing Tang11, Zheng Tian12, Yingxi Xu, PhD13, Ying Wang, MD, PhD14, Min Wang, PhD15, Hong Wang16, Shaowei Qiu, MD17, Runxia Gu, MD18, Jianxiang Wang Sr, MD, PhD19
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Despite advances in chemotherapy and targeted therapies, relapsed and refractory acute myeloid leukemia (AML) remains a major clinical challenge. Immunotherapy is promising, but novel targets with enhanced efficacy and reduced on-target/off-tumor toxicity are urgently needed for AML. In this study, we performed comprehensive plasma membrane proteomic profiling and identified the membrane protein CD180 as a potential immunotherapeutic target.

Using a centrifuge column-based enrichment strategy, membrane proteins were isolated from 11 primary AML samples, CD34+ HSPCs derived from more than 200 healthy donors (including umbilical cord blood (UCB) and mobilized peripheral blood), and CD33+ mature myeloid cells from 7 healthy donors, followed by mass spectrometry-based proteomic analysis. In our data, CD180 demonstrated high expression in primary AML samples compared with normal HSPCs and mature myeloid cells.

We further validated CD180 expression by flow cytometry in 247 AML patients, among which approximately 46.5% patients were CD180-positive (defined as >10% expression). CD180-positive AML cases were enriched among the FAB-M4 and FAB-M5 subtypes. Genetic analysis revealed that CD180 expression was positively associated with MLL-AF9, MLL-AF6, and CBFβ-MYH11 fusions, as well as FLT3-TKD mutations. Conversely, CD180 expression was negatively associated with RUNX1::RUNX1T1 fusion and RUNX1, CSF3R, IDH1 and U2AF1 mutations. Flow cytometry confirmed absent CD180 expression on UCB derived CD34+ HSPCs, with CD180 showing the lowest expression compared with that of CLL1, CD33, and CD123 in both HSCs and HPCs. In normal PBMCs, CD180 expression was mainly restricted to B cells and monocytes, indicating a potentially manageable safety profile.

Using hybridoma technology, we generated high-specificity monoclonal antibodies against CD180 and constructed CD180-directed CAR-T cells with single-chain variable fragments (scFvs). Functionally, CD180 CAR-T cells mediated potent and antigen-specific cytotoxicity against AML cell lines and primary AML samples in vitro. At an effector-to-target (E:T) ratio of 1:1 co-culture, CD180 CAR-T cells completely eliminated OCI-AML2, MV4-11, Molm13, and OCI-AML3 cells within 48 hours. Cytokine releases including TNF-α, IFN-γ, IL-2, IL-4, and IL-10, were significantly increased in the CD180 CAR-T group compared with that of Vector T cells after coculture with AML cell lines or primary AML cells. In vivo, CD180 CAR-T cells significantly reduced tumor burden and prolonged survival in Molm13 and U937 cell line-derived xenograft (CDX) and AML patient-derived xenograft (PDX) models. Safety evaluation showed no impairment of HSPC colony-forming capacity in vitro. In humanized mice reconstituted with UCB derived CD34+ HSPCs, CD180 CAR-T cells showed a favorable safety profile to multilineage hematopoiesis, with only mild effects on mature B cells and monocytes.

Collectively, this study identifies and validates CD180 as a promising immunotherapeutic target for AML through comprehensive membrane proteomic profiling. CD180-directed CAR-T cells demonstrate potent anti-leukemic activity in vitro and in vivo with a favorable safety profile. These findings provide a strong rationale for further development of CD180-directed immunotherapy in AML.

Qianqian Huang: No relevant conflicts of interest to declare.